New York Times runs an article on VC interest in psychedelic medicines, including psilocybin

On February 28th, Jonah Engel Bromwich published an article titled The Capital That Ate Wellness Is Going to Eat Your Mushrooms in The New York Times.

In this piece, Jonah reveals how venture capital firms are beginning to express interest in psychedelics.

Specifically, Jonah discussed how Able Partners – bellwether investors in health and wellbeing companies such as Goop, Moon Juice, and Daily Harvest – is ‘getting into’ the psychedelics space.

Now, Able is an early-stage investor in two companies at the forefront of psychedelic compound (including psilocybin) medical research: ATAI Life Sciences and Compass Pathways (see more about these companies).

You can read the full article here: www.nytimes.com/2020/02/28/style/venture-capital-psychedelics.html